Enlivex Therapeutics Ltd

NASDAQ:ENLV   3:59:52 PM EDT
8.52
-0.25 (-2.85%)
Products, Regulatory, Earnings Announcements

Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Published: 12/03/2020 13:18 GMT
Enlivex Therapeutics Ltd (ENLV) - Enlivex Reports Positive Interim Results From Phase Ii Clinical Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients.
Enlivex Therapeutics Ltd - 100% Patients Treated Through Nov 26, 2020 Had Complete Recovery From Respective Severe/critical Condition.
Enlivex Therapeutics Ltd - Allocetra Treatment Has Been Well Tolerated With No Treatment-related Serious Adverse Events.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.